

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:26:33 ON 08 OCT 2002

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'CAPLUS' ENTERED AT 13:28:00 ON 08 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:28:00 ON 08 OCT 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 13:28:00 ON 08 OCT 2002  
COPYRIGHT (c) 2002 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 13:28:00 ON 08 OCT 2002  
COPYRIGHT (C) 2002 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 13:28:00 ON 08 OCT 2002

FILE 'BIOSIS' ENTERED AT 13:28:00 ON 08 OCT 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 13:28:00 ON 08 OCT 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

=> s inject? and (dermal? or intradermal?)  
L1 39337 INJECT? AND (DERMAL? OR INTRADERMAL?)

=> s l1 and (Hgh or (human growth hormone) or heparin or (dopamine receptor agonist)  
UNMATCHED LEFT PARENTHESIS 'AND (HGH'  
The number of right parentheses in a query must be equal to the  
number of left parentheses.

=> s l1 and (Hgh or (human growth hormone) or heparin or (dopamine receptor  
agonist))  
L2 3556 L1 AND (HGH OR (HUMAN GROWTH HORMONE) OR HEPARIN OR (DOPAMINE  
RECEPTOR AGONIST))

=> s l2 and (nanopart? or nanocapsule# or microcapsule# or micropart? or  
microencapsul? or nanosphere# or microspheres#)  
L3 928 L2 AND (NANOPART? OR NANOCAPSULE# OR MICROCAPSULE# OR MICROPART  
? OR MICROENCAPSUL? OR NANOSPHERE# OR MICROSPHERE#)

=> s l3 and ((hollow needle#) or electroporation or (thermal poration))  
L4 410 L3 AND ((HOLLOW NEEDLE#) OR ELECTROPORATION OR (THERMAL PORATIO  
N))

=> s l4 and microneedle#  
L5 6 L4 AND MICRONEEDLE#

=> d l5 1-6 ibib abs

L5 ANSWER 1 OF 6 USPATFULL

ACCESSION NUMBER: 2002:186398 USPATFULL  
TITLE: SKIN AND MUSCLE-TARGETED GENE THERAPY BY PULSED  
ELECTRICAL FIELD  
INVENTOR(S): DEV, NAGENDU B., SAN DIEGO, CA, UNITED STATES  
HOFMANN, GUNTER A., SAN DIEGO, CA, UNITED STATES  
NOLAN, EDWARD, SAN DIEGO, CA, UNITED STATES  
RABUSSAY, DIETMAR P., SAN DIEGO, CA, UNITED STATES  
TONNESSEN, ARNT, EL CAJON, CA, UNITED STATES  
WIDERA, GEORG, DEL MAR, CA, UNITED STATES  
ZHANG, LEI, SAN DIEGO, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099323	A1	20020725
APPLICATION INFO.:	US 1999-352809	A1	19990713 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92544P	19980713 (60)
	US 1998-109324P	19981120 (60)
	US 1999-126058P	19990325 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LISA A HAILE, GRAY CARY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2189	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	1794	

AB The present invention describes an in vivo method, using pulsed electric field to deliver therapeutic agents into cells of the skin and muscle for local and systemic treatments. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.

L5 ANSWER 2 OF 6 USPATFULL

ACCESSION NUMBER: 2002:179341 USPATFULL  
TITLE: Method for altering drug pharmacokinetics based on  
medical delivery platform  
INVENTOR(S): Pettis, Ronald J., Cary, NC, UNITED STATES  
Harvey, Noel G., Efland, NC, UNITED STATES  
Alchas, Paul G., Wayne, NJ, UNITED STATES  
Down, James, Cary, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002095134	A1	20020718
APPLICATION INFO.:	US 2001-893746	A1	20010629 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-606909, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2001-835243, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 1999-417671, filed on 14 Oct 1999, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998		
NUMBER OF CLAIMS:	64		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		

LINE COUNT: 1328

AB A method for directly delivering whereby a substance is introduced into an **intradermal** space within mammalian skin which involves administering the substance through at least one small gauge **hollow needle** having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between 0.3 mm and 2 mm such that the delivery of the substance occurs at a depth between 0.3 mm and 2 mm.

L5 ANSWER 3 OF 6 USPATFULL

ACCESSION NUMBER: 2002:127015 USPATFULL

TITLE: Localized molecular and ionic transport to and from tissues

INVENTOR(S): Weaver, James C., Sudbury, MA, UNITED STATES  
Anderson, R. Rox, Lexington, MA, UNITED STATES  
Herndon, Terry O., Carlisle, MA, UNITED STATES  
Gowrishankar, T. R., Cambridge, MA, UNITED STATES  
Gift, Elizabeth A., North Reading, MA, UNITED STATES  
Gonzalez, Salvador, Boston, MA, UNITED STATES

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002065533	A1	20020530
APPLICATION INFO.:	US 2001-878155	A1	20010607 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209985P	20000608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	114	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	3120	

AB The present invention relates to methods and devices used for the formation of microconduits in a tissue. The term "microconduit" refers to a small opening, channel, or hole into, or through, a tissue, that allows transfer of materials by liquid flow, and by electrophoresis, the microconduit being formed upon impact of a plurality of accelerated **microparticles** with the surface of the tissue. A method is described for forming at least one microconduit in tissue including the steps of: accelerating a plurality of **microparticles** to a velocity that causes the **microparticles** to penetrate a region of tissue surface upon impingement of the **microparticles** on the tissue surface; and directing the **microparticle** towards the region of tissue surface, thereby causing the **microparticles** to penetrate the tissue and form a microconduit in the tissue. According to an embodiment, **microparticles** are accelerated by being hit with a moving, solid surface. In another embodiment, **microparticles** are accelerated by a flowing gas or liquid. Also described are methods and devices for using microconduits to deliver therapeutic molecules and ions into tissue, or for extraction of chemical analytes out of tissue. Also described is a method of nail piercing to accommodate jewelry.

L5 ANSWER 4 OF 6 USPATFULL

ACCESSION NUMBER: 2001:147937 USPATFULL  
TITLE: Methods and reagents for regulating obesity  
INVENTOR(S): Bernfield, Merton, Boston, MA, United States  
Reizes, Ofer, Newton, MA, United States  
PATENT ASSIGNEE(S): Children's Medical Center Corporation, Boston, MA,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284729	B1	20010904
APPLICATION INFO.:	US 1998-73623		19980506 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-965356, filed on 6 Nov 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Holand & Knight LLP		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1349		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has now been demonstrated that syndecan binds to and interacts with MC4-R, and thereby modulates neuropeptide regulation of body weight, via the agouti/MC4-R signaling pathway. Transgenic animals were made initially using a construct including a cytomegalovirus promoter and the 3' untranslated region, including the polyadenylation site, of the bovine growth hormone gene, as well as cDNA encoding syndecan-1. The mice express the syndecan-1 transgene in many tissues, with expression in the brain occurring preferentially in their hypothalamus. These mice are characterized by elevated levels of circulating syndecan-1 ectodomain and exhibit enormous weight gain after reaching sexual maturity, but have a relatively normal distribution of fat, are completely healthy and heterozygotes reproduce, and show other indicators associated with obesity in humans. Agouti mice which are transgenic for syndecan-1 ectodomain demonstrate that syndecan-1 and agouti interact, potentiating obesity. The double heterozygote shows both an earlier onset, and greater extent, of obesity than either normal agouti or the original transgenic syndecan-1 mice.

Based on these studies and animal models, one can design and test compounds regulating obesity. These mice are also useful in understanding the factors involved in weight regulation and in designing and screening for drugs which are involved in weight regulation and that can either enhance or reduce appetite and activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 6 USPATFULL

ACCESSION NUMBER: 2000:91945 USPATFULL  
TITLE: Gene delivery by **microneedle injection**  
INVENTOR(S): Eriksson, Elof, 5 Lanark Rd., Wellesley Hills, MA,  
United States 02181

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6090790		20000718
APPLICATION INFO.:	US 1997-990442		19971215 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-445265, filed on 19 May 1995, now patented, Pat. No. US 5697901 which is a continuation-in-part of Ser. No. US 1993-76550,		

filed on 11 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-897357, filed on 11 Jun 1992, now patented, Pat. No. US 5423778 which is a continuation-in-part of Ser. No. US 1991-707248, filed on 22 May 1991, now patented, Pat. No. US 5152757 which is a continuation-in-part of Ser. No. US 1989-451957, filed on 14 Dec 1989, now abandoned

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Chambers, Jasmine  
ASSISTANT EXAMINER: Baker, Anne-Marie  
LEGAL REPRESENTATIVE: Quarles & Brady LLP  
NUMBER OF CLAIMS: 3  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 1206

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Direct gene transfer of genetic material into an external or internal target cell site ("microseeding"), in optional combination with a wound treatment chamber, are particularly effective as a means of obtaining long term expression of native or non-native polypeptides in a host. A wide variety of proteins and materials can be expressed, either for secretion into the general blood and lymphatic system, or to alter the properties of the protein, for example, to not express proteins eliciting an immune response. The use of the optional wound chamber system for gene transfer to skin target sites also allows non-invasive assessment of the success of transfer by assaying for the presence of the expressed protein in wound fluid, in contrast to the prior art use of invasive techniques, such as biopsies, in order to achieve the same assessment of early expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 6 USPATFULL

ACCESSION NUMBER: 97:117408 USPATFULL

TITLE: Gene delivery by **microneedle injection**

INVENTOR(S): Eriksson, Elof, 5 Lanark Rd., Wellesley, MA, United States 02181

PATENT ASSIGNEE(S): Eriksson, Elof, Wellesley Hills, MA, United States (U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5697901		19971216
APPLICATION INFO.:	US 1995-445265		19950519 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-76550, filed on 11 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-897357, filed on 11 Jun 1992, now patented, Pat. No. US 5423778 which is a continuation-in-part of Ser. No. US 1991-707248, filed on 22 May 1991, now patented, Pat. No. US 5152757 which is a continuation of Ser. No. US 1989-451957, filed on 14 Dec 1989, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Buiz, Michael Powell  
ASSISTANT EXAMINER: Nguyen, A. T.  
LEGAL REPRESENTATIVE: Quarles & Brady  
NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1129

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Direct gene transfer of genetic material into an external or internal target cell site ("microseeding"), in optional combination with a wound treatment chamber, are particularly effective as a way of obtaining long term expression of native or non-native polypeptides in a host. A wide variety of proteins and materials can be expressed, either for secretion into the general blood and lymphatic system, or to alter the properties of the protein, for example, to not express proteins eliciting an immune response. The use of the optional wound chamber system for gene transfer to skin target sites also allows non-invasive assessment of the success of transfer by assaying for the presence of the expressed protein in wound fluid, in contrast to the prior art use of invasive techniques, such as biopsies, in order to achieve the same assessment of early expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 11 and bolus

L6 2885 L1 AND BOLUS

=> s 16 and (Hgh or (human growth hormone) or heparin or (dopamine receptor agonist))

L7 734 L6 AND (HGH OR (HUMAN GROWTH HORMONE) OR HEPARIN OR (DOPAMINE RECEPTOR AGONIST))

=> s 17 and (multiple or repeat?)

L8 683 L7 AND (MULTIPLE OR REPEAT?)

=> s 18 and pd>6/01

4 FILES SEARCHED...

QUALIFICATION NOT VALID FOR NUMERIC DATA '6/01'

6 FILES SEARCHED...

Numeric data cannot be field qualified.

=>

=> d 18 600-620 ibib abs

L8 ANSWER 600 OF 683 USPATFULL

ACCESSION NUMBER: 96:60798 USPATFULL

TITLE: Cardiac hypertrophy factor and uses therefor

INVENTOR(S): Baker, Joffre, El Granada, CA, United States

Chien, Kenneth, La Jolla, CA, United States

King, Kathleen, Pacifica, CA, United States

Pennice, Diane, Burlingame, CA, United States

Wood, William, San Mateo, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5534615		19960709
APPLICATION INFO.:	US 1994-233609		19940425 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Kim, Hyosuk		

LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E.  
NUMBER OF CLAIMS: 1  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)  
LINE COUNT: 3897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 601 OF 683 USPATFULL  
ACCESSION NUMBER: 96:38781 USPATFULL  
TITLE: Assays and therapeutic methods based on lymphocyte chemoattractants  
INVENTOR(S): Springer, Timothy A., Chestnut Hill, MA, United States  
Roth, Stephen J., Brookline, MA, United States  
Carr, Michelle W., Boston, MA, United States  
PATENT ASSIGNEE(S): Center for Blood Research, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5514555		19960507
APPLICATION INFO.:	US 1993-30764		19930312 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2194		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel assay for lymphocyte chemotaxis. The assay is transendothelial assay using endothelial cells cultured on microporous filters. Lymphocyte transmigration through the filter toward a suspected chemoattractant is measured. Apparatuses for carrying out the assay are also provided. The apparatuses and methods of the present invention can be used for the identification of inhibitors (e.g., antagonists) or promoters (chemoattractants) of the adhesion receptor-mediated migration of leukocytes through the endothelium (extravasation). Such inhibitors and promoters respectively inhibit and promote the inflammatory response, and thus have therapeutic utilities. The inhibitors and promoters are identified by detecting their abilities to respectively inhibit or promote the chemotaxis of lymphocytes in the assay of the invention. The assay of the invention also has diagnostic utilities for detecting a disease or disorder involving a defect in lymphocyte chemotaxis. In a specific embodiment, the invention provides a novel lymphocyte chemoattractant, termed LCA, of molecular weight of about 14,500.+-3,000 daltons. Derivatives and analogs of LCA, and antibodies and antibody fragments thereto are also provided. The invention also relates to therapeutic uses and compositions related to the foregoing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 602 OF 683 USPATFULL

ACCESSION NUMBER: 96:20903 USPATFULL  
 TITLE: Composition useful for in vivo delivery of biologics and methods employing same  
 INVENTOR(S): Grinstaff, Mark W., Pasadena, CA, United States  
 Soon-Shiong, Patrick, Los Angeles, CA, United States  
 Wong, Michael, Champaign, IL, United States  
 Sandford, Paul A., Los Angeles, CA, United States  
 Suslick, Kenneth S., Champaign, IL, United States  
 Desai, Neil P., Los Angeles, CA, United States  
 PATENT ASSIGNEE(S): Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5498421		19960312
APPLICATION INFO.:	US 1994-200235		19940222 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 1993-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Benston, Jr., William E.		
LEGAL REPRESENTATIVE:	Reiter, Stephen E. Pretty, Schroeder, Brueggemann & Clark		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	3321		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided compositions useful for the in vivo delivery of a biologic, wherein the biologic is associated with a polymeric shell formulated from a biocompatible material. The biologic can be associated with the polymeric shell itself, and/or the biologic, optionally suspended/dispersed in a biocompatible dispersing agent, can be encased by the polymeric shell. In another aspect, the biologic associated with polymeric shell is administered to a subject, optionally dispersed in a suitable biocompatible liquid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 603 OF 683 USPATFULL  
 ACCESSION NUMBER: 96:14905 USPATFULL  
 TITLE: Platelet aggregation inhibitors having high specificity for GPIIBIIIA  
 INVENTOR(S): Burnier, John P., Pacifica, CA, United States  
 Gadek, Thomas, Oakland, CA, United States  
 McDowell, Robert S., San Francisco, CA, United States  
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5493007		19960220
APPLICATION INFO.:	US 1994-311835		19940923 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-173716, filed on 23 Dec 1993, now abandoned which is a continuation of Ser. No. US 1993-45566, filed on 9 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-681802, filed on 5 Apr 1991, now abandoned		



DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Warden, Jill  
ASSISTANT EXAMINER: Huff, Sheela J.  
LEGAL REPRESENTATIVE: Winter, Daryl B.  
NUMBER OF CLAIMS: 4  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A peptide containing the tripeptide recognition sequences RGD or KGD in a cycle and an exocyclic group bearing a positive charge is provided. The compound is provided in therapeutic form for administration to a mammal and exhibits high specificity and potency as a platelet aggregation inhibitor without undesirable side effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 604 OF 683 USPATFULL  
ACCESSION NUMBER: 96:12856 USPATFULL  
TITLE: Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals  
INVENTOR(S): Blough, Herbert A., Berwyn, PA, United States  
PATENT ASSIGNEE(S): U.S. Bioscience, Inc., West Conshohocken, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5491135		19960213
APPLICATION INFO.:	US 1993-32234		19930317 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-853454, filed on 18 Mar 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Jones, Dwayne C.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	3264		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are disclosed which utilize the broad spectrum antiviral activity of PALA. This compound and its pharmaceutically acceptable analogs possess potent activity while displaying minimal toxicity and, therefore, are characterized by a relatively high therapeutic index. Compositions optionally containing other therapeutic agents, such as other antiviral agents, are also disclosed and are found to possess synergistic and/or additive antiviral activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 605 OF 683 USPATFULL  
ACCESSION NUMBER: 95:108159 USPATFULL  
TITLE: Method of treating complement mediated disorders  
INVENTOR(S): Fearon, Douglas T., Baltimore, MD, United States  
Klickstein, Lloyd B., Brookline, MA, United States  
Wong, Winnie W., Newton, MA, United States  
Carson, Gerald R., Wellesley, MA, United States  
Concino, Michael F., Newton, MA, United States  
Ip, Stephen H., Sudbury, MA, United States  
Makrides, Savvas C., Bedford, MA, United States  
Marsh, Jr., Henry C., Reading, MA, United States

PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)  
The Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)  
T Cell Sciences, Inc., Needham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5472939		19951205
APPLICATION INFO.:	US 1993-138825		19931019 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-588128, filed on 24 Sep 1990, now patented, Pat. No. US 5256642 which is a continuation-in-part of Ser. No. US 1989-412745, filed on 26 Sep 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-332865, filed on 3 Apr 1989, now patented, Pat. No. US 5212071 which is a continuation-in-part of Ser. No. US 1988-176532, filed on 1 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Draper, Garnette D.		
ASSISTANT EXAMINER:	Ulm, John D.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	9		
NUMBER OF DRAWINGS:	81 Drawing Figure(s); 61 Drawing Page(s)		
LINE COUNT:	4827		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 606 OF 683 USPATFULL  
ACCESSION NUMBER: 95:84198 USPATFULL  
TITLE: [ALA IL-8].sub.77 and [SER IL-8].sub.72 as Leukocyte adhesion inhibitors  
INVENTOR(S): Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States  
Obin, Martin S., Newton Centre, MA, United States  
Baker, Joffre B., El Granada, CA, United States  
Hebert, Caroline A., San Francisco, CA, United States  
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5451399		19950919
APPLICATION INFO.:	US 1992-964525		19921019 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-443131, filed on 29 Nov 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Draper, Garnette D.		
ASSISTANT EXAMINER:	Carlson, K. Cochrane		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	1518		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel polypeptide [Ala IL-8].sub.77 is provided which is a potent modulator of neutrophil functions. The polypeptide factor and related compositions find use as anti-inflammatory agents and as therapeutics for clinical indications in which damage to vascular endothelium and other tissues occurs. The amino acid and nucleotide sequence of the factor and methods for its purification, recombinant production and pharmaceutical use are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 607 OF 683 USPATFULL  
 ACCESSION NUMBER: 95:78080 USPATFULL  
 TITLE: Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease  
 INVENTOR(S): Brenner, Michael B., Sherborn, MA, United States  
 Der Simonian, Harout, Watertown, MA, United States  
 PATENT ASSIGNEE(S): Brigham & Women's Hospital, Boston, MA, United States  
 (U.S. corporation)  
 Dana-Farber Cancer Institute, Boston, MA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5445940		19950829
APPLICATION INFO.:	US 1992-936267		19920826 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-750986, filed on 28 Aug 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Hart, Julia D.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	2012		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are monoclonal antibodies, fragments, and derivatives thereof reactive with an epitope of the T cell receptor alpha chain variable region, V.alpha.12.1, on human T lymphocytes. The monoclonal antibodies are reactive with approximately 2% of CD4.sup.+ T lymphocytes and with approximately 5% of CD8.sup.+ T lymphocytes in peripheral blood cells in normal individuals and define a subset of individuals afflicted with an autoimmune disease, especially rheumatoid arthritis, that exhibit increased expression of the V.alpha.12.1 gene on CD8.sup.+ peripheral blood T lymphocytes when compared to normal individuals. Also provided are methods for diagnosing, treating, and monitoring the progression of

rheumatoid arthritis in a subject using V.alpha.12.1-specific reagents, including antibodies and nucleic acid probes. Higher levels of assurance in the diagnosis of RA can be made by establishing that the expansion of V.alpha.12.1 gene usage is clonal or oligoclonal and that the V.alpha.12.1 expansion correlates with the occurrence of the MHC allele, HLA-DQw2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 608 OF 683 USPATFULL  
ACCESSION NUMBER: 95:3863 USPATFULL  
TITLE: Treatment for atherosclerosis and other cardiovascular and inflammatory diseases  
INVENTOR(S): Medford, Russell M., Atlanta, GA, United States  
Offermann, Margaret K., Atlanta, GA, United States  
Alexander, R. Wayne, Atlanta, GA, United States  
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5380747		19950110
APPLICATION INFO.:	US 1992-969934		19921030 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cintins, Marianne M.		
ASSISTANT EXAMINER:	Jarvis, William R.		
LEGAL REPRESENTATIVE:	Kilpatrick & Cody		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1081		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 609 OF 683 USPATFULL  
ACCESSION NUMBER: 94:102323 USPATFULL  
TITLE: Structure, production and use of heregulin  
INVENTOR(S): Vandlen, Richard L., Hillsborough, CA, United States  
Holmes, William E., Pacifica, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5367060		19941122
APPLICATION INFO.:	US 1992-847743		19920306 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Hill, Jr., Robert J.  
ASSISTANT EXAMINER: Carlson, K. Cochrane  
LEGAL REPRESENTATIVE: Lee, Wendy M.  
NUMBER OF CLAIMS: 27  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 33 Drawing Page(s)  
LINE COUNT: 3698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 610 OF 683 USPATFULL  
ACCESSION NUMBER: 94:99904 USPATFULL  
TITLE: Conformationally restricted biologically active peptides, methods for their production and uses thereof  
INVENTOR(S): Joran, Alvin D., New York, NY, United States  
PATENT ASSIGNEE(S): International Synthecon, LLC, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5364851		19941115
APPLICATION INFO.:	US 1991-714167		19910614 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Russel, Jeffrey E.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1333		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Electrochemical methods, preferably the Kolbe coupling reaction, are utilized to create intramolecularly bridged peptides, segments or peptide isosteres which are conformationally restricted and preferably, biologically active. Preferably, the peptide analogues contain methylene groups bridging particular amino acid side chains. Analogues of a variety of peptide hormones, including insulin, insulin-like growth factors, somatostatin, melanocyte stimulating hormone, and the like are prepared by the above methods. Such peptides are useful as agonists or antagonists for treatment of diseases associated with deficiency of the hormone or dysregulation of hormone activity, as well as for mechanistic studies to understand the interactions between peptide hormones and cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 611 OF 683 USPATFULL  
ACCESSION NUMBER: 94:15755 USPATFULL  
TITLE: 2,6-methano-2H-1-benzoxocincarboxylic acids, esters and amides  
INVENTOR(S): Airey, John E., King of Prussia, PA, United States

Powers, Matthew R., Barto, PA, United States  
Rodriguez, Walter, Douglasville, PA, United States  
Youssefyeh, Raymond D., Princeton Junction,, NJ, United States  
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5288731		19940222
APPLICATION INFO.:	US 1992-925044		19920805 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-620241, filed on 29 Nov 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-582890, filed on 1 Oct 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-186824, filed on 27 Apr 1988, now patented, Pat. No. US 4863921, issued on 5 Sep 1989		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hollrah, Glennon R.		
ASSISTANT EXAMINER:	Rand, Scott C.		
LEGAL REPRESENTATIVE:	Nicholson, James A., Savitzky, Martin F., Parker, III, Raymond S.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1176		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds which are 2,6-methano-2H-1-benzoxocincarboxamides having 5-HT.sub.3 -antagonist properties including unique CNS, antiemetic and gastric prokinetic activities and which are void of any significant D.sub.2 receptor binding affinity, therapeutic compositions and methods of treatment of disorders which result from 5-HT.sub.3 activity using said compounds. Processes for their preparation and the preparation of their intermediates are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 612 OF 683 USPATFULL  
ACCESSION NUMBER: 94:13452 USPATFULL  
TITLE: Detection and purification of activin polypeptide  
INVENTOR(S): Cox, Edward T., Foster City, CA, United States  
Mather, Jennie P., Millbrae, CA, United States  
Sliwkowski, Mary B., San Carlos, CA, United States  
Woodruff, Teresa K., Millbrae, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5286654		19940215
APPLICATION INFO.:	US 1993-12711		19930203 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1991-716826, filed on 19 Jun 1991, now patented, Pat. No. US 5216126		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Y. Christina		
ASSISTANT EXAMINER:	Adams, Arnold E.		
LEGAL REPRESENTATIVE:	Hasak, Janet E.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		

LINE COUNT: 2945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 613 OF 683 USPATFULL

ACCESSION NUMBER: 93:89649 USPATFULL

TITLE: Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof

INVENTOR(S): Fearon, Douglas T., Baltimore, MD, United States

Klickstein, Lloyd B., Brookline, MA, United States

Wong, Winnie W., Newton, MA, United States

Carson, Gerald R., Wellesley, MA, United States

Concino, Michael F., Newton, MA, United States

Ip, Stephen H., Sudbury, MA, United States

Makrides, Savvas, C., Bedford, MA, United States

Marsh, Jr., Henry C., Reading, MA, United States

PATENT ASSIGNEE(S): The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

T Cell Sciences, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5256642		19931026
APPLICATION INFO.:	US 1990-588128		19900924 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-412745, filed on 26 Sep 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-332865, filed on 3 Apr 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-176532, filed on 1 Apr 1988, now abandoned		

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Wax, Robert A.

ASSISTANT EXAMINER: Walsh, Stephen

LEGAL REPRESENTATIVE: PenniPenni

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 81 Drawing Figure(s); 61 Drawing Page(s)

LINE COUNT: 4529

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention further relates to methods for treating thrombotic conditions in humans and animals by administering a composition comprising soluble CR1 and a thrombolytic agent. In particular, the compositions and methods are useful both for reducing reperfusion injury and ameliorating the other effects of myocardial infarction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 614 OF 683 USPATFULL  
ACCESSION NUMBER: 93:48399 USPATFULL  
TITLE: DNA sequences encoding bVEGF120 and hVEGF121 and  
methods for the production of bovine and human vascular  
endothelial cell growth factors, bVEGF.sub.120 and  
hVEGF.sub.121  
INVENTOR(S): Tischer, Edmund G., Palo Alto, CA, United States  
Abraham, Judith A., Sunnyvale, CA, United States  
Fiddes, John C., Palo Alto, CA, United States  
Mitchell, Richard L., Sunnyvale, CA, United States  
PATENT ASSIGNEE(S): Scios Nova Inc., Mountain View, CA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5219739		19930615
APPLICATION INFO.:	US 1990-559041		19900727 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-450883, filed on 14 Dec 1989 which is a continuation-in-part of Ser. No. US 1989-387545, filed on 27 Jul 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hill, Jr., Robert J.		
ASSISTANT EXAMINER:	Allen, Marianne Porta		
LEGAL REPRESENTATIVE:	Shearer, Peter R.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1,2		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2551		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated DNA sequences, expression vectors and transformant cells are  
provided which allow for the large scale production of vascular  
endothelial cell growth factor. The vascular endothelial cell growth  
factor is useful in the treatment of wounds in which neovascularization  
or reendothelialization is required for healing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 615 OF 683 USPATFULL  
ACCESSION NUMBER: 93:48236 USPATFULL  
TITLE: Collagen wound healing matrices and process for their  
production  
INVENTOR(S): Chu, George H., Sunnyvale, CA, United States  
Ogawa, Yasushi, Pacifica, CA, United States  
McPherson, John M., Hopkinton, MA, United States  
Ksander, George, Redwood City, CA, United States  
Pratt, Bruce, Union City, CA, United States  
Hendricks, Diana, Brea, CA, United States  
McMullin, Hugh, San Bruno, CA, United States  
PATENT ASSIGNEE(S): Collagen Corporation, Palo Alto, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5219576		19930615
APPLICATION INFO.:	US 1991-801732		19911203 (7)
DISCLAIMER DATE:	20070821		
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-630299, filed on 19 Dec 1990, now patented, Pat. No. US 5110604 which is a		



division of Ser. No. US 1988-213726, filed on 30 Jun 1988, now patented, Pat. No. US 5024841

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Kishore, G. S.  
LEGAL REPRESENTATIVE: Morrison & Foerster  
NUMBER OF CLAIMS: 4  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)  
LINE COUNT: 714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.<sup>sup.3</sup> and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 616 OF 683 USPATFULL  
ACCESSION NUMBER: 93:44360 USPATFULL  
TITLE: Receptor polypeptides and their production and uses  
INVENTOR(S): Cox, Edward T., Foster City, CA, United States  
Mather, Jennie P., Millbrae, CA, United States  
Sliwowski, Mary B., San Carlos, CA, United States  
Woodruff, Teresa K., Millbrae, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5216126		19930601
APPLICATION INFO.:	US 1991-716826		19910619 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chan, Y. Christina		
ASSISTANT EXAMINER:	Adams, Donald E.		
LEGAL REPRESENTATIVE:	Hasak, Janet E.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2843		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An isolated TGF-.beta. supergene family (TSF) receptor polypeptide is provided. This polypeptide preferably is an inhibin/activin receptor polypeptide and has at least 75% sequence identity with the mature human inhibin/activin receptor sequence. Also provided is a method for purifying TGF-.beta. supergene family members such as inhibin or activin using the polypeptide, and a method for screening for compounds with TGF-.beta. supergene family member activity by contacting the compound with the polypeptide and detecting if binding has occurred and the compound is active.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 617 OF 683 USPATFULL  
ACCESSION NUMBER: 93:24816 USPATFULL  
TITLE: Assay for free IGF-I, IGF-II, and GH levels in body

INVENTOR(S): fluids  
 Mukku, Venkat R., Fremont, CA, United States  
 PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5198340		19930330
APPLICATION INFO.:	US 1991-642509		19910117 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Hasak, Janet E.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1012		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and kit are provided for determining levels in a biological sample of free IGF-I, IGF-II, or GH ligand that is normally associated in the sample with a binding protein. This method involves contacting the body fluid with an immobilized unlabeled capture reagent and incubating at 4.degree.-10.degree. C. for no greater than about 4 hours to bind the free ligand contained in the body fluid; separating the fluid from the immobilized capture reagent; and measuring the level of free ligand now bound to the capture reagent. This method is particularly useful to determine levels of free IGF-I in serum or plasma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 618 OF 683 USPATFULL  
 ACCESSION NUMBER: 93:20691 USPATFULL  
 TITLE: Production of vascular endothelial cell growth factor  
 INVENTOR(S): Tischer, Edmund G., Palo Alto, CA, United States  
 Abraham, Judith A., Sunnyvale, CA, United States  
 Fiddes, John C., Palo Alto, CA, United States  
 Mitchell, Richard L., Sunnyvale, CA, United States  
 PATENT ASSIGNEE(S): California Biotechnology Inc., Mountain View, CA,  
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5194596		19930316
APPLICATION INFO.:	US 1989-450883		19891214 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-387545, filed on 27 Jul 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine M.		
ASSISTANT EXAMINER:	Sidberry, H. F.		
LEGAL REPRESENTATIVE:	Shearer, Peter R.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	2011		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is described an isolated vascular endothelial cell growth factor selected from the group consisting of bovine vascular endothelial cell growth factor of 120 amino acids and human vascular endothelial cell growth factor of 121 amino acids. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization

or reendothelialization is required for healing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 619 OF 683 USPATFULL  
ACCESSION NUMBER: 92:42541 USPATFULL  
TITLE: Method for treating benign prostatic hypertrophy  
INVENTOR(S): Gokcen, Muharrem, Minneapolis, MN, United States  
Guy, Terry J., Chaska, MN, United States  
PATENT ASSIGNEE(S): Immunolytics, Inc., Minneapolis, MN, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5116615		19920526
APPLICATION INFO.:	US 1991-707628		19910530 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Stone, Jacqueline		
LEGAL REPRESENTATIVE:	Merchant, Gould, Smith, Edell, Welter & Schmidt		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3209		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic **injection** of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 620 OF 683 USPATFULL  
ACCESSION NUMBER: 92:35989 USPATFULL  
TITLE: Processes for producing collagen matrixes and methods of using same  
INVENTOR(S): Chu, George H., Sunnyvale, CA, United States  
Ogawa, Yasushi, Pacifica, CA, United States  
McPherson, John M., Framingham, MA, United States  
Ksander, George, Redwood City, CA, United States  
Pratt, Bruce, Union City, CA, United States  
Hendricks, Diana, Brea, CA, United States  
McMullin, Hugh, San Bruno, CA, United States  
PATENT ASSIGNEE(S): Collagen Corporation, Palo Alto, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5110604		19920505
APPLICATION INFO.:	US 1990-630299		19901219 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1988-213726, filed on 30 Jun 1988, now patented, Pat. No. US 5024841		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Page, Thurman K.  
ASSISTANT EXAMINER: Kishore, G. S.  
LEGAL REPRESENTATIVE: Morrison & Foerster  
NUMBER OF CLAIMS: 4  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)  
LINE COUNT: 711

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.<sup>sup.3</sup> and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 6 USPATFULL

ACCESSION NUMBER: 2002:179341 USPATFULL

TITLE: Method for altering drug pharmacokinetics based on medical delivery platform

INVENTOR(S): Pettis, Ronald J., Cary, NC, UNITED STATES  
Harvey, Noel G., Efland, NC, UNITED STATES  
Alchas, Paul G., Wayne, NJ, UNITED STATES  
Down, James, Cary, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002095134	A1	20020718
APPLICATION INFO.:	US 2001-893746	A1	20010629 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-606909, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2001-835243, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 1999-417671, filed on 14 Oct 1999, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998		
NUMBER OF CLAIMS:	64		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Page(s)		
LINE COUNT:	1328		

AB A method for directly delivering whereby a substance is introduced into an **intradermal** space within mammalian skin which involves administering the substance through at least one small gauge **hollow needle** having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between 0.3 mm and 2 mm such that the delivery of the substance occurs at a depth between 0.3 mm and 2 mm.

L8 ANSWER 619 OF 683 USPATFULL  
ACCESSION NUMBER: 92:42541 USPATFULL  
TITLE: Method for treating benign prostatic hypertrophy  
INVENTOR(S): Gokcen, Muharrem, Minneapolis, MN, United States  
Guy, Terry J., Chaska, MN, United States  
PATENT ASSIGNEE(S): Immunolytics, Inc., Minneapolis, MN, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5116615		19920526
APPLICATION INFO.:	US 1991-707628		19910530 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-429966, filed on 31 Oct 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-303809, filed on 27 Jan 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Stone, Jacqueline		
LEGAL REPRESENTATIVE:	Merchant, Gould, Smith, Edell, Welter & Schmidt		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3209		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a composition and method for treating benign prostatic hypertrophy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic **injection** of a safe and therapeutically effective dose of the composition via the transurethral route of administration.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.